MarketPulse

South Korea

7 articles
BenzingaBenzinga··Chandrima Sanyal

South Korea's 55% Rally Masks Risky Bet on AI Chip Dominance

South Korea's 55% market surge is concentrated in semiconductors via Samsung and SK Hynix, creating hidden concentration risk in Korea ETFs like $EWY despite apparent diversification.
EEMVEAEWYVWOEWJ+1AI chipsETF
The Motley FoolThe Motley Fool··Brett Schafer

Nasdaq Correction Creates Buying Opportunities in Latin American and Asian E-Commerce Leaders

Nasdaq enters correction territory. MercadoLibre and Coupang offer compelling value despite steep declines from peaks.
NVDAAMZNMELICPNGfintechLatin America
The Motley FoolThe Motley Fool··Brett Schafer

Coupang Bets on Nvidia Partnership to Accelerate AI-Driven Logistics

Coupang partners with Nvidia on AI-powered logistics platform while recovering from data breach scandal. Stock trades at attractive 1.0x P/S despite 44% decline, with revenue growth resuming.
NVDACPNGexpansionvaluation
BenzingaBenzinga··Prnewswire

Anixa Secures Korean Patent for Breast Cancer Vaccine, Bolstering IP Portfolio

Anixa Biosciences secures patent protection in South Korea for breast cancer vaccine technology, advancing its IP portfolio as Phase 1 trial shows 74% immune response rate.
ANIXintellectual propertyclinical trial
GlobeNewswire Inc.GlobeNewswire Inc.··Nxera Pharma Co., Ltd.

Nxera Pharma Pursues South Korea Insomnia Market With Daridorexant Filing

Nxera Pharma seeks South Korean approval for insomnia drug daridorexant, already marketed globally, with expected 2027 regulatory decision.
SGIOYPhase 3 trialregulatory approval
The Motley FoolThe Motley Fool··Brett Schafer

Coupang Stock Faces Headwinds but Maintains Growth Momentum

Coupang stock down 26% after data breach, but maintains 20% revenue growth and positive cash flow. Depressed valuation presents opportunity amid regulatory risks.
AMZNCPNGvaluatione-commerce
Investing.comInvesting.com··Mike Zaccardi, Cfa, Cmt

Emerging Market Equities Extend Outperformance Against U.S. Large-Cap Index

Emerging market equities significantly outperform U.S. large-cap stocks, with IEMG up 44% versus modest S&P 500 gains, driven by broad-based regional strength.
SPYEEMEWYEWZVWO+1emerging marketsoutperformance